- Home
- VOR vs LU Comparison
VOR vs LU Comparison
Compare VOR & LU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VOR | LU |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VOR | LU |
|---|---|---|
| Price | $22.35 | $1.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 1 |
| Target Price | ★ $45.33 | $2.00 |
| AVG Volume (30 Days) | 697.7K | ★ 786.4K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.50 | $1.19 |
| 52 Week High | $49.95 | $4.57 |
Technical Indicators
Market Signals| Indicator | VOR | LU |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 35.37 |
| Support Level | $21.90 | $1.20 |
| Resistance Level | $24.44 | $1.45 |
| Average True Range (ATR) | 1.13 | 0.05 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 12.44 | 7.69 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.